AcuCort AB (publ) (NGM:ACUC)

Market Cap	171.84M
Revenue (ttm)	7.72M
Net Income (ttm)	-17.40M
Shares Out	226.11M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,765
Average Volume	378,989
Open	0.7740
Previous Close	0.7420
Day's Range	0.7450 - 0.7740
52-Week Range	0.4600 - 1.2600
Beta	1.39
RSI	47.59
Earnings Date	Apr 25, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ACUC

Financial Performance

In 2023, AcuCort AB's revenue was 6.59 million, an increase of 31.24% compared to the previous year's 5.02 million. Losses were -13.69 million, -7.42% less than in 2022.